Drößler, Linda
Lehmann, Clara
Töpelt, Karin
Nierhoff, Dirk
Vehreschild, Jörg J.
Rybniker, Jan
Hallek, Michael
Fischer, Julia
Stormberg, Verena
Fätkenheuer, Gerd
Wieland, Ulrike
Jung, Norma
Article History
Received: 23 July 2018
Accepted: 16 January 2019
First Online: 28 January 2019
Compliance with ethical standards
:
: None to declare. LD, KT, GF, JF, VS, UW, JR, DN stated no conflicts of interest related to the article. JJV has served at the speakers bureau of Pfizer, Merck, Gilead, Basilea and Astellas, received research funding from Astellas, Gilead, Infectopharm, Merck/MSD, Basilea and Pfizer, has received travel assistance from Astellas, Gilead, Merck/MSD and Basilea, and is a consultant to Astellas, Gilead, Basilea and Merck/MSD. MH has received consultancy fee, speaker`s honoraria and research support from Roche/Gentech. CL has received travel grants from Gilead and BMS and speaking honorarium from Gilead, Janssen, ViiV and Abbvie. NJ has received lecture fees from Labor Stein, Novartis, Gilead, MSD, Infectopharm and travel grants from Gilead, Novartis and Basilea.